Real-world data in retinal diseases treated with anti-vascular endothelial growth factor (anti-VEGF) therapy - a systematic approach to identify and characterize data sources
| dc.rights.license | open | en_US |
| dc.contributor.author | DAIEN, V. | |
| dc.contributor.author | ELDEM, B. M. | |
| dc.contributor.author | TALKS, J. S. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | KOROBELNIK, Jean-Francois
ORCID: 0000-0002-4438-9535 IDREF: 028739272 | |
| dc.contributor.author | MITCHELL, P. | |
| dc.contributor.author | FINGER, R. P. | |
| dc.contributor.author | SAKAMOTO, T. | |
| dc.contributor.author | WONG, T. Y. | |
| dc.contributor.author | EVUARHERHE, O. | |
| dc.contributor.author | CARTER, G. | |
| dc.contributor.author | CARRASCO, J. | |
| dc.date.accessioned | 2020-06-16T07:30:39Z | |
| dc.date.available | 2020-06-16T07:30:39Z | |
| dc.date.issued | 2019-10-16 | |
| dc.identifier.issn | 1471-2415 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/7942 | |
| dc.description.abstractEn | BACKGROUND: Real-world data (RWD) has been a valuable addition to the scientific literature regarding treatment pathways, clinical outcomes and characteristics of patients with retinal diseases in recent years. Registries, observational studies and patient databases are often used for real-world research. However, there is limited information for each data source on the design, consistency, data captured, limitations and usability for assessing research questions. Using a systematic approach, we identified RWD sources for patients with retinal diseases and assessed them for completeness of data relating to different outcomes. METHODS: A systematic literature review was carried out to identify RWD sources for patients with retinal disease. Potentially relevant articles published between 2006 and 2016 were screened following electronic searches in Embase and MEDLINE. Congress and supplementary searches were undertaken to identify RWD sources that may not be referenced in full publications. For each data source, availability and quantity of data on baseline status, clinical outcomes, treatment and management, safety, and patient-reported and economic burden were assessed using a bespoke completeness assessment tool based on International Consortium for Health Outcomes Measurement guidelines for macular degeneration. Completeness of data for each area of interest in each data source was assessed and rated using a 'good-moderate-poor' rating system based on availability and quantity of available data. Each data source was then given an overall score based on its score for each of the 7 areas of interest. RESULTS: A total of 128 RWD sources from 32 countries were identified. Of the identified sources, 64 sources from 16 countries of interest were analyzed. Most of these sources provided information on baseline status and clinical outcomes and treatment, but few collected data on economic and patient-reported burden. Of the RWD sources analyzed, 10 scored highly in the overall completeness assessment, collecting data on most or all of the areas of interest; these sources are considered to be robust data sources for performing ophthalmology real-world studies. CONCLUSIONS: The study provides a comprehensive list of RWD sources for patients with retinal disease, many of which will be useful for conducting real-world studies in the field of ophthalmology. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution 4.0 International (CC BY 4.0) | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.subject.en | LEHA | |
| dc.title.en | Real-world data in retinal diseases treated with anti-vascular endothelial growth factor (anti-VEGF) therapy - a systematic approach to identify and characterize data sources | |
| dc.title.alternative | BMC Ophthalmol | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1186/s12886-019-1208-9 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 31619195 | en_US |
| bordeaux.journal | BMC Ophthalmol | en_US |
| bordeaux.page | 206 | en_US |
| bordeaux.volume | 19 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 1 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.team | LEHA_BPH | |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.export | false | |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=BMC%20Ophthalmol&rft.date=2019-10-16&rft.volume=19&rft.issue=1&rft.spage=206&rft.epage=206&rft.eissn=1471-2415&rft.issn=1471-2415&rft.au=DAIEN,%20V.&ELDEM,%20B.%20M.&TALKS,%20J.%20S.&KOROBELNIK,%20Jean-Francois&MITCHELL,%20P.&rft.genre=article |
